Benign Prostatic Hyperplasia Therapeutics
1. Avodart patent expiration
Treatment: Method of inhibiting 5 alpha testosterone reductase enzyme with dutasteride or its derivative and treating androgen responsive/mediated disease including Read More
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5998427 | WAYLIS THERAP | Androstenones |
Sep, 2013
(12 years ago) | |
| US5846976 | WAYLIS THERAP | Androstenone derivative |
Sep, 2013
(12 years ago) | |
| US5565467 | WAYLIS THERAP | Androstenone derivative |
Nov, 2015
(10 years ago) | |
Drugs and Companies using DUTASTERIDE ingredient
Market Authorisation Date: 20 November, 2001
Dosage: CAPSULE
How can I launch a generic of AVODART before it's drug patent expiration?
More Information on Dosage
AVODART family patents
2. Cialis patent expiration
Treatment: Erectile dysfunction; Treatment of erectile dysfunction; Treatment of sexual dysfunction
CIALIS IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6943166 (Pediatric) | LILLY | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
Oct, 2020
(5 years ago) | |
| US6821975 | LILLY | Beta-carboline drug products |
Nov, 2020
(5 years ago) | |
| US6140329 | LILLY | Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence |
Jul, 2016
(9 years ago) | |
| US7182958 | LILLY | β-carboline pharmaceutical compositions |
Apr, 2020
(5 years ago) | |
|
US5859006 (Pediatric) | LILLY | Tetracyclic derivatives; process of preparation and use |
May, 2018
(7 years ago) | |
|
US6821975 (Pediatric) | LILLY | Beta-carboline drug products |
May, 2021
(4 years ago) | |
| US5859006 | LILLY | Tetracyclic derivatives; process of preparation and use |
Nov, 2017
(8 years ago) | |
|
US7182958 (Pediatric) | LILLY | β-carboline pharmaceutical compositions |
Oct, 2020
(5 years ago) | |
| US6943166 | LILLY | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
Apr, 2020
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-641) | Oct 06, 2014 |
| New Indication(I-642) | Oct 06, 2014 |
| M(M-219) | Feb 15, 2021 |
| Pediatric Exclusivity(PED) | Aug 15, 2021 |
Drugs and Companies using TADALAFIL ingredient
Market Authorisation Date: 07 January, 2008
Dosage: TABLET
How can I launch a generic of CIALIS before it's drug patent expiration?
More Information on Dosage
CIALIS family patents
3. Rapaflo patent
expiration
Treatment: Use in the treatment of the signs and symptoms of benign prostatic hyperplasia (bph)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6015819 | ABBVIE | Use of alpha-1C specific compounds to treat benign prostatic hyperplasia |
Nov, 2012
(13 years ago) | |
| US5387603 | ABBVIE | 1,5,7-trisubstituted indoline compounds and salts thereof |
Dec, 2018
(7 years ago) | |
| US5403847 | ABBVIE | Use of α1C specific compounds to treat benign prostatic hyperlasia |
Nov, 2012
(13 years ago) | |
| US5780485 | ABBVIE | Use of α1c specific compounds to treat benign prostatic hyperplasia |
Nov, 2012
(13 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 08, 2013 |
Drugs and Companies using SILODOSIN ingredient
NCE-1 date: 08 October, 2012
Market Authorisation Date: 08 October, 2008
Dosage: CAPSULE
How can I launch a generic of RAPAFLO before it's drug patent expiration?
More Information on Dosage
RAPAFLO family patents
4. Uroxatral patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6149940 | ADVANZ PHARMA | Tablet with controlled release of alfuzosine chlorhydrate |
Aug, 2017
(8 years ago) | |
|
US6149940 (Pediatric) | ADVANZ PHARMA | Tablet with controlled release of alfuzosine chlorhydrate |
Feb, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-97) | Dec 15, 2013 |
| Pediatric Exclusivity(PED) | Jun 15, 2014 |
Drugs and Companies using ALFUZOSIN HYDROCHLORIDE ingredient
Market Authorisation Date: 12 June, 2003
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of UROXATRAL before it's drug patent expiration?
More Information on Dosage
UROXATRAL family patents